The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis-Reference-Cited by-同舟云学术

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

Published:2009-02-05 Issue:2 Volume:46 Page:145-154
ISSN:0940-5429
Container-title:Acta Diabetologica
language:en
Short-container-title:Acta Diabetol

Author:

Pantalone Kevin M.,Kattan Michael W.,Yu Changhong,Wells Brian J.,Arrigain Susana,Jain Anil,Atreja Ashish,Zimmerman Robert S.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00592-008-0090-3.pdf

Reference23 articles.

1. The University Group Diabetes Program (1975) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy. Diabetes 24(Suppl 1):65–184

2. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837–853

3. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood–glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352(9131):854–865

4. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356(24):2457–2471

5. GlaxoSmithKline (2007) Study no. ZM2005/00181/01: Avandia Cardiovascular Event Modeling Project. Available at: http://ctr.gsk.co.uk/Summary/Rosiglitazone/III_CVmodeling.pdf . Accessed 15 Sept 2007

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes;European Heart Journal;2023-08-25

2. Effectiveness of apabetalone and some other indirect epigenetic-oriented drugs in the treatment of heart failure;Cardiovascular Therapy and Prevention;2023-05-09

3. Effect of metformin on adverse outcomes in T2DM patients: Systemic review and meta-analysis of observational studies;Frontiers in Cardiovascular Medicine;2022-09-23

4. Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy;Cardiovascular Diabetology;2022-09-01

5. Role of Physiotherapy in managing type 2 diabetes mellitus: A systematic review;Journal of Diabetology;2022